You are here

biobucks

Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

Fierce Biotech

Thu, 01/6/22 - 12:36 pm

Generate Biomedicines

drug development

artificial intelligence

Astellas becomes latest Dyno gene therapy partner with $1.6B biobucks pact to join Roche, Novartis, Sarepta

Fierce Biotech

Wed, 12/1/21 - 11:51 pm

Dyno Therapeutics

Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron

Endpoints

Tue, 11/23/21 - 09:51 am

Nykode Therapeutics

infectious disease

Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech

Fierce Biotech

Tue, 11/2/21 - 10:53 am

protein degradation

Dunad Therapeutics

Cytokines claimed spotlight due to COVID-19. Now, Merck will work with Synthekine to understand their role in autoimmune disorders

Fierce Biotech

Mon, 11/1/21 - 10:56 am

drug development

J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race

Fierce Biotech

Mon, 10/4/21 - 11:08 am

bispecific antibodies

Takeda taps Selecta for $1.1B gene therapy research pact

Fierce Biotech

Mon, 10/4/21 - 10:43 am

Selecta Biosciences

Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs

Fierce Biotech

Thu, 09/30/21 - 10:52 am

neuropsychiatric

Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table

Fierce Biotech

Thu, 07/22/21 - 11:15 am

protein degradation

GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's

Fierce Biotech

Fri, 07/2/21 - 11:00 am

neurodegenerative disease

Alzheimer's disease

Johnson & Johnson culls $1.6B argenx blood cancer drug collab

Fierce Biotech

Mon, 06/7/21 - 11:02 am

Astellas quietly cuts Cytokinetics R&D pact as $450M-plus in biobucks goes up in smoke

Fierce Biotech

Mon, 05/3/21 - 10:51 am

Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset

Fierce Biotech

Mon, 03/1/21 - 10:32 am

Bristol Myers Squibb pens $1.3B biobucks pact with Molecular Templates, axes Celgene CAR-T asset

Fierce Biotech

Fri, 02/12/21 - 11:03 am

Bristol-Myers Squibb

Molecular Templates

AbbVie puts $2B on the table for I-Mab cancer collab as biotech nabs $418M raise

Fierce Biotech

Fri, 09/4/20 - 02:43 pm

I-Mab Biopharma

After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program

Fierce Biotech

Tue, 09/1/20 - 10:59 am

Jounce Therapeutics

Gilead Sciences

Bristol-Myers Squibb

immuno-oncology

Pages